Reported Earlier, ACELYRIN Confirms Unsolicited $3/Share Offer From Concentra Biosciences Amid Pending Alumis Merger

Author: Benzinga Newsdesk | February 21, 2025 02:18am

ACELYRIN confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN's development programs or intellectual property.

On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (NASDAQ:ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject to approval by the stockholders of both companies and satisfaction of other customary closing conditions.

Posted In: ALMS SLRN